Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (2017 - 2025)

Historic Shares Outstanding for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $94.5 million.

  • Crinetics Pharmaceuticals' Shares Outstanding rose 1695.55% to $94.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.5 million, marking a year-over-year increase of 1695.55%. This contributed to the annual value of $92.9 million for FY2024, which is 3630.51% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Shares Outstanding stood at $94.5 million for Q3 2025, which was up 1695.55% from $94.1 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Shares Outstanding peaked at $94.5 million during Q3 2025, and registered a low of $4.8 million during Q1 2022.
  • For the 5-year period, Crinetics Pharmaceuticals' Shares Outstanding averaged around $62.1 million, with its median value being $54.7 million (2023).
  • In the last 5 years, Crinetics Pharmaceuticals' Shares Outstanding crashed by 8552.26% in 2022 and then skyrocketed by 102949.79% in 2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Shares Outstanding (Quarter) stood at $47.6 million in 2021, then increased by 13.19% to $53.9 million in 2022, then rose by 26.54% to $68.2 million in 2023, then skyrocketed by 36.31% to $92.9 million in 2024, then rose by 1.75% to $94.5 million in 2025.
  • Its last three reported values are $94.5 million in Q3 2025, $94.1 million for Q2 2025, and $93.5 million during Q1 2025.